Xylo Bio

Xylo Bio operates in the emerging neuropsychiatric drug-development segment, where companies are attempting to convert psychedelic science into regulated, scalable medicines. Its stated differentiation is the development of non-hallucinogenic or selectively acting neuroplastogens rather than conventional psychedelic treatments that produce acute perceptual effects. XYL-1001 is positioned as a 5-HT2A-selective molecule intended to enhance neuroplasticity while avoiding a psychedelic experience, with major depressive disorder as an initial target. The company also frames its programs as potential alternatives or complements to established SSRI treatment. Xylo Bio’s $15.0 million in reported funding across five rounds, including an $8 million 2024 seed round and a $3 million grant, places it in the venture-backed early clinical-development tier rather than among heavily capitalized commercial biopharma companies. Its competitive case therefore rests primarily on selective receptor engineering, a small-molecule pharmaceutical approach, and progression of XYL-1001 into the clinical stage.

Xylo Bio shows a progression from company formation and early discovery toward clinical-stage development. Founded in 2021, the company raised an initial seed round of $798,941 in USD terms on Oct 1, 2021, followed by a $3.23 million seed round on Oct 27, 2022. Its largest disclosed financing was an $8 million seed round announced on Jun 2, 2024 and led by Tenmile, supplemented by a $3 million grant announced on Oct 29, 2024. The January 2025 rebrand from Psylo to Xylo coincided with board appointments and pipeline progress, indicating an effort to establish a distinct corporate and development identity. By Sep 15, 2026, XYL-1001 had reached a clinical-stage milestone focused on major depressive disorder. Overall, the clearest inflection point is the transition from funded discovery work to clinical development.